Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2016 | Highlights from ASH 2016: whole-genome sequencing to identify genomic lesions in ALL

Anthony Moorman, PhD from Newcastle University, Newcastle, UK provides highlights from the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Dr Moorman provides detail on a paper presented by a German study group, which used whole-genome sequencing (WGS) to identify genomic lesions in acute lymphoblastic leukemia (ALL) patients. What made this trial unique was its focus on high-risk patients who had relapsed following allogeneic stem-cell transplantation. From this trial, the group were able to identify patients with targetable mutations who could benefit from treatments that are already available. This technique of characterizing high-risk disease could greatly benefit patients with high-risk ALL. This video has been supported by Incyte through an unrestricted educational grant.